Brief: Calliditas To Recognize Milestone Payment Related To Approval Of Kinpeygo In Q3
26/07/2024 16:03
July 26 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* PARTNER STADA RECEIVES EUROPEAN COMMISSION DECISION FOR FULL APPROVAL OF KINPEYGO® FOR THE
TREATMENT OF IGA NEPHROPATHY
* APPROVAL TRIGGERS A MILESTONE PAYMENT OF TEN MILLION EUR TO CALLIDITAS
* MILESTONE PAYMENT WILL BE RECOGNIZED AS REVENUE IN Q3
Source text for Eikon: ID:nWkr9TcxKd
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations